# A Clinical Study on the Treatment of Metastatic Colorectal Cancer at the Second-line or Beyond.

> **NCT07395063** · PHASE2 · NOT_YET_RECRUITING · sponsor: **The Fourth Affiliated Hospital of Zhejiang University School of Medicine** · enrollment: 68 (estimated)

## Conditions studied

- Metastatic Colorectal Cancer (CRC)

## Interventions

- **DRUG:** Irinotecan liposome combined with capecitabine, bevacizumab and camrelizumab

## Key facts

- **NCT ID:** NCT07395063
- **Lead sponsor:** The Fourth Affiliated Hospital of Zhejiang University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-02-01
- **Primary completion:** 2029-02-01
- **Final completion:** 2029-02-01
- **Target enrollment:** 68 (ESTIMATED)
- **Last updated:** 2026-02-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07395063

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07395063, "A Clinical Study on the Treatment of Metastatic Colorectal Cancer at the Second-line or Beyond.". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT07395063. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*